CARBOGEN AMCIS CEO Mark Griffiths Appointed to Dishman Board of Directors
CARBOGEN AMCIS, the Swiss-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced that Mark C. Griffiths, global chief executive officer of Dishman and CARBOGEN AMCIS, has joined the board of directors of Dishman Pharmaceuticals and Chemicals Ltd.
The appointment was made public by Shri Arpit J. Vyas, managing director,Dishman Pharmaceuticals and Chemicals Ltd.“We are excited to welcome Mark to the board of Dishman. Mark’s leadership at the helm of CARBOGEN AMCIS has turned the company into a success story in the pharmaceutical industry, leading to an increase in business from 63 to 100 million CHF since his appointment. We look forward to a path of continued success together,” said Vyas. Griffiths has served as chief executive officer since 2011 and has been associated with CARBOGEN AMCIS as director of operations and chief executive officer for almost ten years. He also worked for the Dishman Group as operations advisor overseeing the design and construction of the group’s large-scale manufacturing facilities for commercial supply of Highly Potent APIs (HPAPIs) in Shanghai, China, and Ahmedabad, India.
Griffiths has over 31 years of relevant industrial experience delivering high added value technical and operational solutions within the pharmaceutical and fine chemical industry. Qualified as an engineer and having gained significant experience in the management of complex, multi-task, multi-input projects, he brings a cross-functional ability to anticipate and optimize technical, operational and management issues. Griffiths has designed, built and managed facilities ranging in function from research and development to manufacturing. Griffiths holds a Master of Science in engineering from Bristol University, UK.
Dishman is a leading global outsourcing partner for the pharmaceutical industry, offering a rich portfolio of development, scale-up and manufacturing services that straddle the entire pharmaceutical value chain. The company offers cost-effective, high-quality research, development and manufacturing services that include production and supply of tailor-made, high-quality Intermediates and generic APIs to the global pharmaceutical industry. Its global presence includes multiple manufacturing sites in Europe, India, and China – making it one of the most geographically diversified players in the industry.
The Dishman board of directors consists of Shri Janmejay R. Vyas, Chairman & Managing Director; Mrs. Deohooti J. Vyas, Whole-Time Director; Shri Arpit J. Vyas, Managing Director; Shri Yagneshkumar B. Desai, Director; Shri Sanjay S. Majmudar, Director; and Shri Ashok C. Gandhi, Director.
CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd., Ahmedabad, India.
Dishman Group (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.